Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Oct 1;56(4):2002554.
doi: 10.1183/13993003.02554-2020. Print 2020 Oct.

Confronting and mitigating the risk of COVID-19 associated pulmonary aspergillosis

Darius Armstrong-James  1   2 , Jonathan Youngs  3 , Tihana Bicanic  3 , Alireza Abdolrasouli  4 , David W Denning  5 , Elizabeth Johnson  6 , Varun Mehra  7 , Tony Pagliuca  7 , Brijesh Patel  8 , Johanna Rhodes  9 , Silke Schelenz  10 , Anand Shah  9   11 , Frank L van de Veerdonk  12 , Paul E Verweij  12 , P Lewis White  13 , Matthew C Fisher  9   2
Affiliations
Editorial

Confronting and mitigating the risk of COVID-19 associated pulmonary aspergillosis

Darius Armstrong-James et al. Eur Respir J. .

Abstract

Cases of COVID-19 associated pulmonary aspergillosis (CAPA) are being increasingly reported and physicians treating patients with COVID-19-related lung disease need to actively consider these fungal co-infections https://bit.ly/3feuGsQ

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: D. Armstrong-James reports grants and personal fees from Pulmocide Ltd and Gilead Sciences, outside the submitted work. Conflict of interest: J. Youngs reports funding from the UK and Ireland Gilead Fellowship Programme. Conflict of interest: T. Bicanic reports grants and personal fees for lectures from Gilead Sciences Ltd, personal fees for lectures from Pfizer, outside the submitted work. Conflict of interest: A. Abdolrasouli has received speaker honoraria from Gilead Sciences Ltd, outside the submitted work. Conflict of interest: D.W. Denning and family hold founder shares in F2G Ltd, a University of Manchester spin-out antifungal discovery company; D.W. Denning acts or has recently acted as a consultant to Scynexis, Pulmatrix, Pulmocide, Zambon, iCo Therapeutics, Mayne Pharma, Biosergen, and Fujifilm; and has been paid for talks on behalf of Hikma, Gilead, Merck, Mylan and Pfizer; D.W. Denning is a longstanding member of the Infectious Disease Society of America Aspergillosis Guidelines group, the European Society for Clinical Microbiology and Infectious Diseases Aspergillosis Guidelines group. Conflict of interest: E. Johnson has nothing to disclose. Conflict of interest: V. Mehra reports personal fees for lectures from Pfizer, Novartis, Incyte and Gilead Sciences, grants from MSD, outside the submitted work. Conflict of interest: T. Pagliuca reports personal fees for advisory board work from Gilead, MSD and Pfizer, outside the submitted work. Conflict of interest: B. Patel has nothing to disclose. Conflict of interest: J. Rhodes has nothing to disclose. Conflict of interest: S. Schelenz reports personal fees for lectures from Gilead Sciences and Pfizer, outside the submitted work. Conflict of interest: A. Shah reports grant funding from Gilead Sciences and Vertex Pharmaceuticals, and speaker fees from Gilead Sciences and Pfizer. Conflict of interest: F.L. van de Veerdonk has nothing to disclose. Conflict of interest: P.E. Verweij has received research grants from Gilead Sciences, F2G Ltd, Pfizer, Thermofisher and Merck, has served on an advisory board for Gilead Sciences, Mundipharma and F2G, and has received speaker honoraria from F2G, Mundipharma, Pfizer and Gilead Sciences. Conflict of interest: P.L. White reports personal fees from Gilead, Pfizer and F2G, grants from Bruker, outside the submitted work. Conflict of interest: M.C. Fisher reports grants and personal fees for lectures from Gilead Sciences Ltd, outside the submitted work.

Figures

FIGURE 1
FIGURE 1
Proposed screening and diagnostic algorithm for coronavirus disease-2019 associated pulmonary aspergillosis (CAPA). BAL: bronchoalveolar lavage; BDG: (1–3)-β-D-glucan; TA: tracheal aspirate; Asp Ag: aspergillus antigen; AF: antifungal; IA: invasive aspergillosis; GM: galactomannan; EORTC: European Organization for Research and Treatment of Cancer; NBL: non-directed bronchoalveolar lavage; PCP: Pneumocystis pneumonia.
See this image and copyright information in PMC

References

    1. Zhou F, Yu T, Du R, et al. . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054–1062. - PMC - PubMed
    1. Chen N, Zhou M, Dong X, et al. . Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395: 507–513. doi:10.1016/S0140-6736(20)30211-7 - DOI - PMC - PubMed
    1. Rawson TM, Moore LSP, Zhu N, et al. . Bacterial and fungal co-infection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis 2020: in press [10.1093/cid/ciaa530]. - DOI - PMC - PubMed
    1. Hwang DM, Chamberlain DW, Poutanen SM, et al. . Pulmonary pathology of severe acute respiratory syndrome in Toronto. Mod Pathol 2005; 18: 1–10. doi:10.1038/modpathol.3800247 - DOI - PMC - PubMed
    1. Wang H, Ding Y, Li X, et al. . Fatal aspergillosis in a patient with SARS who was treated with corticosteroids. N Engl J Med 2003; 349: 507–508. doi:10.1056/NEJM200307313490519 - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources